# Sermorelin References: The Cited GHRH(1-29) Literature

> Sermorelin references: the full cited literature behind this digest — pediatric growth, older-men GH/IGF-1, pharmacokinetics, cognition, and the men's-health secretagogue studies, with DOIs and PubMed links.

Every figure on this site traces to one of these studies. Author-year, journal, DOI, and PubMed link for each.

## How the citations work

Each numbered reference below corresponds to the inline markers used across the digest. The set is deliberately compact — the core human GH-axis studies, the pharmacokinetics, the cognition trial of the stabilized analog, the men's-health secretagogue work, and the editorials that frame the adult anti-aging caution — rather than an exhaustive bibliography. Where a finding belongs to the analog tesamorelin rather than to sermorelin, the citation and the surrounding text say so.

## References

[1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[2] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. (NCT00257712) https://pubmed.ncbi.nlm.nih.gov/22869065/
[7] Sigalos JT, Pastuszak AW, Allison A, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017;11(6):1752-1757. https://pubmed.ncbi.nlm.nih.gov/28830317/
[8] Sigalos JT, Pastuszak AW. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. https://pubmed.ncbi.nlm.nih.gov/32257855/
[9] Veldhuis JD, Bowers CY. Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp. J Clin Endocrinol Metab. 2009;94:2544-50. https://pubmed.ncbi.nlm.nih.gov/19351731/
[10] Veldhuis JD, et al. Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy. Eur J Endocrinol. 2005;153:577-86. https://pubmed.ncbi.nlm.nih.gov/16189179/
[11] Veldhuis JD, et al. Testosterone blunts feedback inhibition of growth hormone secretion by experimentally elevated insulin-like growth factor-I concentrations. J Clin Endocrinol Metab. 2005;90:1613-7. https://pubmed.ncbi.nlm.nih.gov/15585557/
[12] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. https://pubmed.ncbi.nlm.nih.gov/39537825/
[13] Schier T, Guldner J, Colla M, et al. Changes in sleep-endocrine activity after growth hormone-releasing hormone depend on time of administration. J Neuroendocrinol. 1997;9(3):201-205. https://pubmed.ncbi.nlm.nih.gov/9089471/
[14] Vijayakumar A, et al. Role of pulsatile growth hormone (GH) secretion in the regulation of lipolysis in fasting humans. Clin Diabetes Endocrinol. 2022;8(1):1. https://pubmed.ncbi.nlm.nih.gov/35101148/

---

A stippled reading of the sermorelin record — each GH and IGF-1 figure dotted back to the study that measured it, the formerly-approved-now-compounded history set straight, and the bare plate where the adult anti-aging data thin left honestly unworked; no clinic behind the plate and nothing here dosed, dispensed, or sold.